Moomoo AI 已提取核心信息
CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.
CRISPR Therapeutics AG, a biotechnology company, has entered into a significant investment agreement with certain institutional investors on February 13, 2024. The agreement involves the issuance of 3,916,082 common shares at a par value of CHF 0.03 per share, with the shares being offered at a price of $71.50 each. This offering is expected to generate gross proceeds of approximately $280 million before the deduction of estimated offering expenses. The transaction is supported by a shelf registration statement previously filed with the SEC on July 29, 2021. The investment agreement includes standard representations, warranties, closing conditions, termination clauses, and indemnification obligations. The details of the agreement are disclosed in the company's Form 8-K filing with the SEC, along with the legal opinion of Walder Wyss AG regarding the share issuance.
生物技术公司CRISPR Therapeutics AG已于2024年2月13日与某些机构投资者签订了一项重大投资协议。该协议涉及发行3,916,082股普通股，面值为每股0.03瑞士法郎，每股发行价格为71.50美元。在扣除预计的发行费用之前，此次发行预计将产生约2.8亿美元的总收益。该交易得到了先前于2021年7月29日向美国证券交易委员会提交的货架注册声明的支持。投资协议包括标准陈述、担保、成交条件、终止条款和赔偿义务。该协议的细节在该公司向美国证券交易委员会提交的8-K表格以及Walder Wyss AG关于股票发行的法律意见书中披露。
生物技术公司CRISPR Therapeutics AG已于2024年2月13日与某些机构投资者签订了一项重大投资协议。该协议涉及发行3,916,082股普通股，面值为每股0.03瑞士法郎，每股发行价格为71.50美元。在扣除预计的发行费用之前，此次发行预计将产生约2.8亿美元的总收益。该交易得到了先前于2021年7月29日向美国证券交易委员会提交的货架注册声明的支持。投资协议包括标准陈述、担保、成交条件、终止条款和赔偿义务。该协议的细节在该公司向美国证券交易委员会提交的8-K表格以及Walder Wyss AG关于股票发行的法律意见书中披露。
有用
没用